GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
GemVax AS, a subsidiary of Pharmexa A/S, is developing GV-1001, an injectable formulation of a promiscuous MHC class II peptide derived from the telomerase reverse transcriptase catalytic subunit (hTERT), for the potential treatment of solid tumors, including pancreatic, liver and NSCLC. GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer.